Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, multicentre, open-label, post-marketing study to evaluate the safety and efficacy of ripasudil in patients with glaucoma (including SG) or Ocular Hypertension over 2 years

Next Previous
Trial Profile

A prospective, multicentre, open-label, post-marketing study to evaluate the safety and efficacy of ripasudil in patients with glaucoma (including SG) or Ocular Hypertension over 2 years

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ripasudil (Primary)
  • Indications Angle-closure glaucoma; Glaucoma; Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ROCK-J

Most Recent Events

  • 12 Feb 2022 Results (n=3374) assessing the long-term safety and effectiveness of ripasudil in Japanese patients with glaucoma or ocular hypertension, published in the Advances in Therapy.
  • 08 Feb 2019 New trial record
  • 04 Jan 2019 Three month interim results (n=3058 safety analysis, n=3016 efficacy analysis) published in the Advances in Therapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top